SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors aggressively reposition for the AI hardware supercycle, with institutional flow intensifying ahead of upcoming earnings. The community is actively discussing the stock's role in the enterprise AI infrastructure buildout, while contrasting its valuation and integration strength against competitors in the data center space.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is drawing significant community attention as investors debate its long-term viability, potential share dilution, and the impact of leadership disputes following a recent private placement investment. While some bulls are betting on a recovery fueled by excitement around the broader space sector and upcoming high-profile industry events, skeptics are expressing concerns over financial transparency, the lack of immediate revenue, and potential insider selling.

Telefonaktiebolaget LM Ericsson engages in the provision of telecommunications equipment and related services to mobile and fixed network operators. It operates through the following segments: Networks, Cloud Software, Services, Enterprise, and Other. The Networks segment supports all radio-access technologies and offers hardware, software and related services for both radio access and transport. The Cloud Software segment offers solutions for core networks, business and operational support systems, network design and optimization, and managed network services. The Other segment refers to the media business and other non-allocated business. Segment-level information has also been presented to Other. The company was founded by Lars Magnus Ericsson in 1876 and is headquartered in Kista, Sweden.

Telefonaktiebolaget L M Ericsson - ADR

LM Ericsson Telephone Co.

Ericsson is trending following a massive multi-year deal with AT&T to build out an open radio access network in the U.S., a development that is sparking intense discussion around its competitive positioning against Nokia. The community is actively debating the long-term implications of this contract, with many investors weighing whether this signals a major growth catalyst or if the transition to open-standard architecture will invite future margin pressure.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The Dow Jones Industrial Average is hitting record highs as the broader market finds resilience, driven by strong earnings in AI and semiconductor sectors. Despite community concerns regarding high inflation, geopolitical tensions, and consumer pessimism, investors are debating whether this momentum reflects genuine economic strength or a vulnerable, bubble-like environment.

Zoracles

Zoracles is currently capturing community attention as investors debate its long-term potential against a backdrop of broader crypto market volatility and the highly anticipated government policy changes. Discussion is heavily split between those focused on short-term accumulation during recent price dips and participants highlighting the project's creator-focused utility within the Base ecosystem as a catalyst for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following the quiet launch of Meta's 'Forum' app, with the community actively debating whether this represents a true competitive threat or just another failed attempt at cloning the platform's unique discussion model. Investors remain divided as the stock faces continued volatility, with many analyzing the company's long-term growth prospects, user-generated data value, and recent competitive landscape shifts.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing a parabolic price surge driven by heavy institutional momentum, derivative-linked buying, and speculation surrounding its strategic role in Nvidias new AI-focused CPU architecture. While the stock has reached all-time highs, the community remains sharply divided between investors celebrating a historic squeeze and critics highlighting extreme valuation concerns, high levels of insider selling, and the risks of a potential reversal.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals is currently a focal point for investors as it navigates a transition toward an orphan drug pipeline, centered on its ifetroban platform and an asset sale to Apotex. The community is actively discussing the stock's low float structure and upcoming catalyst milestones, such as clinical trial data updates and the progress of its regulatory roadmaps.

Vale SA engages in the production and exportation of iron ore, pellets, manganese, and iron alloys. It operates through the following segments: Iron Solutions, Energy Transition Materials and Others. The Iron Solutions segment includes the production and extraction of iron ore, iron ore pellets, manganese, other ferrous products, and logistic services. The Energy Transition Materials segment involves the production and extraction of nickel and its by-products. Others includes the revenues and cost of other products, services, research and development, investments in joint ventures and associates of other business. The company was founded on June 1, 1942 and is headquartered in Rio de Janeiro, Brazil.

Vale S.A. - ADR

Vale S.A.

Vale is currently the center of active community debate, with bullish investors highlighting its role in the critical minerals supply chain and attractive dividend yield, while bearish traders point to operational hurdles and institutional hedging through increased put activity.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as investors weigh its potential as a strategic acquisition target for major tech firms against concerns about sector-wide volatility and intense competition from industry incumbents. While the community remains divided over recent price performance and insider selling, many point to its robust partnerships with AI leaders and its perceived valuation discount as evidence of long-term upside potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...

Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...

Allogene Therapeutics (NASDAQ:ALLO)  Shares Down 6%   - Should You Sell?

Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6% - What's Next...

HC Wainwright Issues Optimistic Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Allogene Therapeutics in a report released on Thursday, April 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.15) per share for th...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat...

Allogene Therapeutics (NASDAQ:ALLO) Trading Up 13.1% Following Analyst Upgrade

Allogene Therapeutics (NASDAQ:ALLO) Trading 13.1% Higher After Analyst Upgrade...

Allogene Therapeutics (NASDAQ:ALLO) Upgraded to "Neutral" at JPMorgan Chase & Co.

JPMorgan Chase & Co. raised Allogene Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Thursday...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

ALLO
Allogene Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ALLO News

ALLOAllogene Therapeutics Inc